Table 1. Social, Demographic, and Clinical Variables Pertaining to 1113 Patients Treated With or Without Neoadjuvant Chemotherapy.
| Variable | Patients Treated With Neoadjuvant Chemotherapy | P Value | |
|---|---|---|---|
| No | Yes | ||
| Totals, No. (%) | 781 (70.2) | 332 (29.8) | |
| Age, median (IQR), y | 68 (61-75) | 66 (58-72) | <.001 |
| Sex, No. (%) | |||
| Female | 162 (20.7) | 90 (27.1) | .02 |
| Male | 619 (79.3) | 242 (72.9) | |
| Race/ethnicity, No. (%) | |||
| White | 740 (94.8) | 311 (93.7) | .02 |
| Black | 12 (1.5) | 15 (4.5) | |
| Hispanic or Latino | 29 (3.7) | 8 (2.4) | |
| Other | 29 (3.7) | 6 (1.8) | |
| Marital status, No. (%) | |||
| Married or living together | 551 (70.7) | 237 (71.8) | .48 |
| Separated/divorced | 81 (10.4) | 29 (8.8) | |
| Single (never married) | 68 (8.7) | 36 (10.9) | |
| Widowed | 76 (9.8) | 28 (8.5) | |
| Unknown | 3 (0.4) | 0 | |
| Education, No. (%) | |||
| ≤High school | 127 (35.4) | 68 (31.6) | .26 |
| College or some college | 165 (46.0) | 94 (43.7) | |
| Graduate or professional degree | 40 (11.1) | 27 (12.6) | |
| Unknown | 27 (7.52) | 26 (12.1) | |
| Primary insurance, No. (%) | |||
| Private | 148 (19.0) | 106 (31.9) | <.001 |
| Medicare | 405 (51.9) | 178 (53.6) | |
| Medicaid | 25 (3.2) | 19 (5.7) | |
| Self-paying or uninsured | 25 (3.2) | 11 (3.3) | |
| Elixhauser comorbidity, mediana | 4 | 3 | .08 |
| Histologic type, No. (%) | |||
| Urothelial carcinoma | 622 (79.60) | 229 (69.0) | <.001 |
| Squamous cell carcinoma | 15 (1.9) | 6 (1.8) | |
| Adenocarcinoma | 10 (1.3) | 1 (0.3) | |
| Other | 134 (17.1) | 96 (28.9) | |
| Clinical AJCC stage, No. (%) | |||
| I (≤T1NxMx) | 289 (37.0) | 11 (3.3)b | <.001 |
| II (T2NxMx) | 395 (50.6) | 228 (68.7) | |
| III (T3NxMx) | 56 (7.2) | 61 (18.4) | |
| IV (T4NxMx) | 34 (4.4) | 31 (9.3) | |
| Unknown | 7 (0.9) | 1 (0.3) | |
| Pathologic AJCC stage, No. (%) | |||
| 0 (T0/Ta/isN0M0) | 205 (26.2) | 112 (33.7) | <.001 |
| I (T1N0M0) | 82 (10.5) | 14 (4.2) | |
| II (T2N0M0) | 118 (15.1) | 36 (10.8) | |
| III (T3N0M0) | 169 (21.6) | 69 (20.8) | |
| IV (T4N0-3M0-1) | 193 (24.7) | 101 (30.4) | |
| Unknown | 14 (1.8) | 0 | |
| Chemotherapy regimen, No. (%); cycles, mean (SD) No. | |||
| Gemcitabine-cisplatin | NAc | 204 (61.4); 3.7 (2.2) | <.001 |
| Gemcitabine-carboplatin | NA | 32 (9.6); 4.4 (3.6) | |
| ddMVAC | NA | 46 (13.9); 3.3 (0.9) | |
| Other | NA | 50 (15.1); 3.96 (2.1) | |
Abbreviations: AJCC, American Joint Committee on Cancer; ddMVAC, dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin; NA, not applicable.
a
The Elixhauser comorbidity index categorizes comorbidities based on International Classification of Diseases, Ninth Revision and International Statistical Classification of Diseases and Related Health Problems, Tenth Revision diagnosis codes found in administrative data.21
b
cT1 based on transurethral resection with radiographic or clinical evidence of invasive/advanced disease.
c
Number of cycles not applicable because these patients did not receive neoadjuvant chemotherapy.